Updated:
Novarcel Group
Lili Huang established Novarcel Group as a single-family office based in Hong Kong. The firm maintains a diversified book spanning public equities, private...
Novarcel Group
Lili Huang established Novarcel Group as a single-family office based in Hong Kong. The firm maintains a diversified book spanning public equities, private equity, and private credit. Novarcel Group targets growth equity and venture stages from Series A through Series D. It has recorded co-investments in Sirnaomics Ltd. with Wang Xuning, Daofeng He, Angela Cui He, Smooth River Limited, and Thinkreal Holdings Limited. Geographic reach covers Asia and North America. Asset classes include fund-of-funds commitments alongside direct biotechnology holdings. The firm lists no additional offices or disclosed headcount. No dated operational events from the past 24 months appear in available records. Novarcel Group operates through a concentrated ownership structure with Lili Huang as ultimate beneficial owner, limiting external mandates and preserving direct control over allocation decisions.
General information
Firm type
Single Family Office
Year founded
—
AUM
43 (Altss estimate)
Location
Region
Asia
Country
Hong Kong
City
Hong Kong
Corporate office
Hong Kong, Hong Kong
Principals
Lili Huang
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Novarcel Group?
Lili Huang serves as founder and ultimate beneficial owner. No additional investment committee members are named in available records.
Does Novarcel Group participate in fund commitments or only direct deals?
The firm uses both fund-of-funds vehicles and direct co-investments. Confirmed activity includes Series C2 and Series E rounds in Sirnaomics Ltd.
Which sectors does Novarcel Group target?
Documented focus areas are Healthcare Services and Digital Health, with emphasis on biotechnology.
Where does Novarcel Group invest geographically?
Allocations span Asia and North America.
What investment stages does Novarcel Group typically target?
Activity centers on Growth, Series A, Series B, Series C, and Series D rounds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: